FGD2

Across TCGA pan-cancer cohorts, FGD2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated FGD2 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FGD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FGD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LUAD, READ, and UCEC are the cancer types where FGD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.066	0.793	<.001	36	view →
READ	OS	Median	II,III,IV	0.054	0.934	<.001	24	view →
UCEC	DFS	Median	All	0.935	0.616	.010	12	view →
PRAD	OS	Median	All	0.157	0.883	<.001	12	view →
COAD	OS	Median	III,IV	0.189	0.702	.006	6	view →
LGG	DFS	Median	All	0.555	0.832	.010	4	view →
SKCM	DFS	Median	II,III,IV	0.757	0.536	.018	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

FGD2–LUAD (DFS)

Open the LUAD breakdown →